Information on outcomes of COVID-19 in pulmonary arterial hypertension (PAH) patients is limited to a few case series and surveys. Here, we describe our experience at a large Pulmonary Hypertension Center in New York City at the height of the pandemic. We performed a retrospective chart review of eleven consecutive PAH patients who were diagnosed with SARS-CoV-2 infection. We analyzed demographics, PAH severity, risk factors for COVID-19, and COVID-19 severity and outcomes. We found in our sample that 63.6% of patients required intensive care, and there was a 45.45% overall mortality. Most patients had a known COVID-19 contact and mean duration of symptoms prior to presentation was 12 days. Only 4/11 (36%) patients presented to a center with pulmonary hypertension expertise, all of whom survived. Most patients had at least moderate pulmonary hypertension with an average REVEAL score of 7.81 despite double or triple PAH therapy. Our cases series underscores the gravity of SARS-CoV-2 infection in patients with PAH. It also suggests possible interventions to prevent unfavorable outcomes such as preserving social distancing, PAH management optimization, and early and preferential presentation to a center with specialized expertise in PAH.
【저자키워드】 COVID-19, SARS-CoV-2, clinical outcomes, pulmonary arterial hypertension, 【초록키워드】 pandemic, therapy, intensive care, social distancing, SARS-COV-2 infection, severity, COVID-19 severity, Intervention, outcome, risk factor, pulmonary, New York City, outcomes, management, Patient, moderate, pulmonary hypertension, retrospective, Contact, demographics, overall mortality, average, center, PAH, Prevent, analyzed, performed, diagnosed, required, Most patient, case sery, survived, duration of symptom, 【제목키워드】 pulmonary, New York City, Artery, observation, center, PAH,